Background Breast cancer is the leading cause of cancer-related mortality among women in developing nations. NFKBIA encodes the inhibitors of nuclear factor-kappaB (NF-κB), which plays a critical role in modulating inflammation and carcinogenic processes. However, no prior studies were conducted to determine the association between NFKBIA polymorphisms and breast cancer susceptibility in the Bangladeshi population. Therefore, we aimed to examine the association of the NFKBIA (rs696) polymorphism with breast cancer risk in Bangladeshi women. Methods This case-control study involved 168 breast cancer patients and 150 healthy volunteers, utilizing polymerase chain reaction-restriction fragment length polymorphism. We assessed the p -value, odds ratio (OR), and 95% confidence interval (CI) to analyze the level of risk association of rs696. Results The cancer patients exhibited a higher mutant allele frequency than the controls. Breast cancer patients who are carriers of the mutant allele demonstrated a markedly elevated risk in two genetic models, including the additive model 2 (GG vs. AA: OR = 2.09, 95% CI = 1.03–4.23, p -value=0.042) and the dominant model (AG + GG vs. AA: OR = 1.73, 95% CI = 1.07–2.78, p -value=0.025). Moreover, the analysis of allele frequency indicated that carriers of the mutant allele G among breast cancer patients exhibited a significantly elevated risk compared to carriers of the wild-type A allele (G vs. A: OR = 1.42, 95% CI = 1.04–1.96, p -value=0.029). Conclusion Our results suggest that NFKBIA (rs696) might be associated with an increased risk of breast cancer in Bangladeshi women. However, we recommend studies in the future with a larger sample size to validate these findings.
Meem et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: